questionsmedicales.fr
Maladies endocriniennes
Maladies de l'hypophyse
Hyperpituitarisme
Hyperprolactinémie
Hyperprolactinémie : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Hyperprolactinémie
Prolactine
Prolactine
Hyperprolactinémie
Galactorrhée
Dysfonction érectile
Hyperprolactinémie
Asymptomatique
Symptômes
5
Maux de tête
Tumeur hypophysaire
Libido
Dysfonction sexuelle
Prévention
5
Mode de vie
Alimentation équilibrée
Antipsychotiques
Médicaments
Gestion du stress
Méditation
Examens réguliers
Anomalies hormonales
Traitements
5
Cabergoline
Agonistes de la dopamine
Chirurgie
Tumeur hypophysaire
Effets secondaires
Nausées
Surveillance médicale
Traitement
Complications
5
Santé osseuse
Densité osseuse
Cancer
Hyperprolactinémie
Grossesse
Fausses couches
Troubles visuels
Nerf optique
Facteurs de risque
5
Antécédents familiaux
Tumeurs hypophysaires
Femmes
Hyperprolactinémie
Maladies endocriniennes
Hypothyroïdie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hyperprolactinémie : Questions médicales les plus fréquentes",
"headline": "Hyperprolactinémie : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hyperprolactinémie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-02",
"dateModified": "2026-07-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hyperprolactinémie"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hyperpituitarisme",
"url": "https://questionsmedicales.fr/mesh/D006964",
"about": {
"@type": "MedicalCondition",
"name": "Hyperpituitarisme",
"code": {
"@type": "MedicalCode",
"code": "D006964",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C19.700.355"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Hyperprolactinémie",
"alternateName": "Hyperprolactinemia",
"code": {
"@type": "MedicalCode",
"code": "D006966",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ilan Shimon",
"url": "https://questionsmedicales.fr/author/Ilan%20Shimon",
"affiliation": {
"@type": "Organization",
"name": "Institute of Endocrinology, Beilinson Hospital, Petach Tikva, Israel. ilanshi@clalit.org.il."
}
},
{
"@type": "Person",
"name": "Robert Krysiak",
"url": "https://questionsmedicales.fr/author/Robert%20Krysiak",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland."
}
},
{
"@type": "Person",
"name": "Bogusław Okopień",
"url": "https://questionsmedicales.fr/author/Bogus%C5%82aw%20Okopie%C5%84",
"affiliation": {
"@type": "Organization",
"name": "Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland."
}
},
{
"@type": "Person",
"name": "Lucio Vilar",
"url": "https://questionsmedicales.fr/author/Lucio%20Vilar",
"affiliation": {
"@type": "Organization",
"name": "Division of Endocrinology, Hospital das Clinicas, Federal University of Pernambuco, Recife, Brazil, lvilarf@gmail.com."
}
},
{
"@type": "Person",
"name": "Clarice Freitas Vilar",
"url": "https://questionsmedicales.fr/author/Clarice%20Freitas%20Vilar",
"affiliation": {
"@type": "Organization",
"name": "Pernambuco Endocrine Research Center, Recife, Brazil."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Roles of long noncoding RNA in triple-negative breast cancer.",
"datePublished": "2023-10-05",
"url": "https://questionsmedicales.fr/article/37795578",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cam4.6600"
}
},
{
"@type": "ScholarlyArticle",
"name": "Long noncoding RNA NONHSAT122636.2 attenuates myocardial inflammation and apoptosis in myocarditis.",
"datePublished": "2024-08-16",
"url": "https://questionsmedicales.fr/article/39150929",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0307779"
}
},
{
"@type": "ScholarlyArticle",
"name": "Characterization of the long noncoding RNA transcriptome in human preimplantation embryo development.",
"datePublished": "2023-09-29",
"url": "https://questionsmedicales.fr/article/37770818",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10815-023-02951-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "An increase in a long noncoding RNA ANRIL in peripheral plasma is an indicator of stable angina.",
"datePublished": "2023-10-16",
"url": "https://questionsmedicales.fr/article/37852142",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clinsp.2023.100289"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association of long noncoding RNA GAS5 gene polymorphism with progression of diabetic kidney disease.",
"datePublished": "2024-08-13",
"url": "https://questionsmedicales.fr/article/39239549",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7150/ijms.99545"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies endocriniennes",
"item": "https://questionsmedicales.fr/mesh/D004700"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies de l'hypophyse",
"item": "https://questionsmedicales.fr/mesh/D010900"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hyperpituitarisme",
"item": "https://questionsmedicales.fr/mesh/D006964"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hyperprolactinémie",
"item": "https://questionsmedicales.fr/mesh/D006966"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hyperprolactinémie - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hyperprolactinémie",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-08-25",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hyperprolactinémie",
"description": "Comment diagnostiquer l'hyperprolactinémie ?\nQuels examens complémentaires sont nécessaires ?\nQuels niveaux de prolactine indiquent une hyperprolactinémie ?\nQuels symptômes peuvent indiquer un diagnostic ?\nPeut-on avoir une hyperprolactinémie sans symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D006966?mesh_terms=RNA,+Long+Noncoding#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hyperprolactinémie",
"description": "Quels sont les symptômes courants de l'hyperprolactinémie ?\nL'hyperprolactinémie peut-elle causer des maux de tête ?\nComment l'hyperprolactinémie affecte-t-elle la libido ?\nLes femmes enceintes peuvent-elles avoir une hyperprolactinémie ?\nQuels signes indiquent une galactorrhée ?",
"url": "https://questionsmedicales.fr/mesh/D006966?mesh_terms=RNA,+Long+Noncoding#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hyperprolactinémie",
"description": "Peut-on prévenir l'hyperprolactinémie ?\nQuels modes de vie peuvent réduire les risques ?\nLes médicaments peuvent-ils causer l'hyperprolactinémie ?\nComment gérer le stress pour prévenir l'hyperprolactinémie ?\nLes examens réguliers sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D006966?mesh_terms=RNA,+Long+Noncoding#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hyperprolactinémie",
"description": "Quels traitements sont disponibles pour l'hyperprolactinémie ?\nQuand faut-il envisager une chirurgie ?\nLes traitements sont-ils efficaces ?\nY a-t-il des effets secondaires aux traitements ?\nPeut-on arrêter le traitement après amélioration ?",
"url": "https://questionsmedicales.fr/mesh/D006966?mesh_terms=RNA,+Long+Noncoding#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hyperprolactinémie",
"description": "Quelles complications peuvent survenir avec l'hyperprolactinémie ?\nL'hyperprolactinémie peut-elle affecter la santé osseuse ?\nY a-t-il un risque accru de cancer ?\nComment l'hyperprolactinémie affecte-t-elle la grossesse ?\nLes troubles visuels sont-ils fréquents ?",
"url": "https://questionsmedicales.fr/mesh/D006966?mesh_terms=RNA,+Long+Noncoding#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hyperprolactinémie",
"description": "Quels sont les facteurs de risque de l'hyperprolactinémie ?\nLe stress peut-il être un facteur de risque ?\nLes femmes sont-elles plus à risque ?\nL'âge influence-t-il le risque d'hyperprolactinémie ?\nLes maladies endocriniennes sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D006966?mesh_terms=RNA,+Long+Noncoding#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer l'hyperprolactinémie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un dosage sanguin de prolactine est effectué pour confirmer l'hyperprolactinémie."
}
},
{
"@type": "Question",
"name": "Quels examens complémentaires sont nécessaires ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une IRM de l'hypophyse peut être réalisée pour détecter des tumeurs."
}
},
{
"@type": "Question",
"name": "Quels niveaux de prolactine indiquent une hyperprolactinémie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux supérieurs à 25 ng/mL chez les femmes et 15 ng/mL chez les hommes sont préoccupants."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des irrégularités menstruelles, galactorrhée ou dysfonction érectile peuvent alerter."
}
},
{
"@type": "Question",
"name": "Peut-on avoir une hyperprolactinémie sans symptômes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent avoir des niveaux élevés sans présenter de symptômes."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de l'hyperprolactinémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent galactorrhée, irrégularités menstruelles et infertilité."
}
},
{
"@type": "Question",
"name": "L'hyperprolactinémie peut-elle causer des maux de tête ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maux de tête peuvent survenir, surtout en cas de tumeur hypophysaire."
}
},
{
"@type": "Question",
"name": "Comment l'hyperprolactinémie affecte-t-elle la libido ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut réduire la libido et provoquer des dysfonctions sexuelles chez les hommes."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes peuvent-elles avoir une hyperprolactinémie ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les niveaux de prolactine augmentent naturellement pendant la grossesse."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une galactorrhée ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "La galactorrhée se manifeste par l'écoulement de lait des seins en dehors de l'allaitement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'hyperprolactinémie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode spécifique de prévention, mais un suivi médical régulier aide."
}
},
{
"@type": "Question",
"name": "Quels modes de vie peuvent réduire les risques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et l'exercice, peut aider."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils causer l'hyperprolactinémie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments comme les antipsychotiques peuvent augmenter les niveaux de prolactine."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pour prévenir l'hyperprolactinémie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de gestion du stress comme la méditation peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Les examens réguliers sont-ils importants ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers permettent de détecter précocement des anomalies hormonales."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour l'hyperprolactinémie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les agonistes de la dopamine comme la cabergoline sont souvent prescrits."
}
},
{
"@type": "Question",
"name": "Quand faut-il envisager une chirurgie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est envisagée si une tumeur hypophysaire provoque des symptômes sévères."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la plupart des patients répondent bien aux traitements médicamenteux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires comme des nausées ou des vertiges peuvent survenir."
}
},
{
"@type": "Question",
"name": "Peut-on arrêter le traitement après amélioration ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est conseillé de continuer le traitement sous surveillance médicale même après amélioration."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'hyperprolactinémie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent l'infertilité, l'ostéoporose et des troubles visuels."
}
},
{
"@type": "Question",
"name": "L'hyperprolactinémie peut-elle affecter la santé osseuse ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des niveaux élevés de prolactine peuvent entraîner une diminution de la densité osseuse."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'y a pas de lien direct prouvé entre hyperprolactinémie et cancer."
}
},
{
"@type": "Question",
"name": "Comment l'hyperprolactinémie affecte-t-elle la grossesse ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des complications comme des fausses couches ou des accouchements prématurés."
}
},
{
"@type": "Question",
"name": "Les troubles visuels sont-ils fréquents ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles visuels peuvent survenir si une tumeur hypophysaire exerce une pression sur le nerf optique."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de l'hyperprolactinémie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des tumeurs hypophysaires et certains médicaments."
}
},
{
"@type": "Question",
"name": "Le stress peut-il être un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à l'augmentation des niveaux de prolactine."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes sont plus souvent touchées par l'hyperprolactinémie que les hommes."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'hyperprolactinémie ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente généralement avec l'âge, surtout chez les femmes en périménopause."
}
},
{
"@type": "Question",
"name": "Les maladies endocriniennes sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme l'hypothyroïdie peuvent augmenter le risque d'hyperprolactinémie."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 21/07/2026
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Institute of Endocrinology, Beilinson Hospital, Petach Tikva, Israel. ilanshi@clalit.org.il.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel. ilanshi@clalit.org.il.
Publications dans "Hyperprolactinémie" :
3 publications dans cette catégorie
Affiliations :
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
Publications dans "Hyperprolactinémie" :
3 publications dans cette catégorie
Affiliations :
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
Publications dans "Hyperprolactinémie" :
2 publications dans cette catégorie
Affiliations :
Division of Endocrinology, Hospital das Clinicas, Federal University of Pernambuco, Recife, Brazil, lvilarf@gmail.com.
Pernambuco Endocrine Research Center, Recife, Brazil, lvilarf@gmail.com.
Publications dans "Hyperprolactinémie" :
2 publications dans cette catégorie
Affiliations :
Pernambuco Endocrine Research Center, Recife, Brazil.
Publications dans "Hyperprolactinémie" :
2 publications dans cette catégorie
Affiliations :
Division of Endocrinology, Hospital das Clinicas, Federal University of Pernambuco, Recife, Brazil.
Publications dans "Hyperprolactinémie" :
2 publications dans cette catégorie
Affiliations :
Psychiatric Hospital "Sveti Ivan", Jankomir 11, 10090 Zagreb, Croatia, sandra.pisk@pbsvi.hr.
Publications dans "Hyperprolactinémie" :
2 publications dans cette catégorie
Affiliations :
Institute of Endocrinology, Beilinson Hospital, Petach Tikva, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Publications dans "Hyperprolactinémie" :
2 publications dans cette catégorie
Affiliations :
Maccabi Health Care Services, Tel Aviv, Israel.
Publications dans "Hyperprolactinémie" :
2 publications dans cette catégorie
Affiliations :
Institute of Endocrinology, Beilinson Hospital, Petach Tikva, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Publications dans "Hyperprolactinémie" :
2 publications dans cette catégorie
Affiliations :
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. amit.akirov@gmail.com.
Institute of Endocrinology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, 49100, Israel. amit.akirov@gmail.com.
Publications dans "Hyperprolactinémie" :
2 publications dans cette catégorie
Affiliations :
Department of Animal Science, University of California, Davis, Davis, CA 95616, USA.
Publications dans "Hyperprolactinémie" :
2 publications dans cette catégorie
Affiliations :
Agriculture and Agri-Food Canada, Sherbrooke R&D Centre, Sherbrooke, QC J1M 0C8, Canada. Electronic address: chantal.farmer@canada.ca.
Publications dans "Hyperprolactinémie" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
Publications dans "Hyperprolactinémie" :
1 publication dans cette catégorie
Affiliations :
Division of Endocrinology, IRCCS San Raffaele Hospital, San Raffaele Vita-Salute University, Via Olgettina, 58, Milan, 20132, Italy.
Publications dans "Hyperprolactinémie" :
1 publication dans cette catégorie
Affiliations :
Division of Endocrinology, IRCCS San Raffaele Hospital, San Raffaele Vita-Salute University, Via Olgettina, 58, Milan, 20132, Italy.
Publications dans "Hyperprolactinémie" :
1 publication dans cette catégorie
Affiliations :
Endocrinology/Medicine Departments, Hospital Sant Pau, Barcelona, Spain.
Publications dans "Hyperprolactinémie" :
1 publication dans cette catégorie
Affiliations :
Division of Endocrinology, IRCCS San Raffaele Hospital, San Raffaele Vita-Salute University, Via Olgettina, 58, Milan, 20132, Italy. giustina.andrea@hsr.it.
Publications dans "Hyperprolactinémie" :
1 publication dans cette catégorie
Publications dans "Hyperprolactinémie" :
1 publication dans cette catégorie
Publications dans "Hyperprolactinémie" :
Long noncoding RNAs (lncRNAs) play crucial roles in regulating various hallmarks in cancers. Triple-negative (Estrogen receptor, ER; Human epidermal growth factor receptor 2, HER2; Progesterone recept...
We reviewed the current literature on the roles of lncRNAs in the pathogenesis, therapy resistance, and prognosis of patients with TBNC....
LncRNAs are associated with TNBC pathogenesis, therapy resistance, and prognosis. For example, lncRNAs such as small nucleolar RNA host gene 12 (SNHG12), highly upregulated in liver cancer (HULC) HOX ...
In this review, we outline the functions of various lncRNAs along with their molecular mechanisms involved in the pathogenesis, therapeutic resistance of TBNC. Also, the prognostic implications of lnc...
The main pathological change of myocarditis is an inflammatory injury of cardiomyocytes. Long noncoding RNAs (lncRNAs) are closely related to inflammation, and our previous study showed that different...
RNA expression was measured by quantitative reverse-transcription polymerase chain reaction (RT-qPCR). Lipopolysaccharide (LPS) was used to induce inflammation in human cardiomyocytes (HCMs). The expr...
NONHSAT122636.2 was dynamically expressed in patients with myocarditis and negatively correlated with inflammation severity. The overexpression of NONHSAT122636.2 improved inflammatory injury in LPS-s...
NONHSAT122636.2 attenuates myocardial inflammation and apoptosis in myocarditis. Additionally, its expression decreases in the peripheral blood of children suffering from myocarditis and in patients w...
Infertility remains a human health burden globally. Only a fraction of embryos produced via assisted reproductive technologies (ARTs) develop to the blastocyst stage in vitro. lncRNA abundance changes...
scRNA-seq data and SUPeR-seq data were used to investigate the lncRNA profiles of human preimplantation embryos. The top 50 highly expressed unique and shared lncRNAs in each stage of preimplantation ...
The lncRNA profiles of human preimplantation embryos in the E-MTAB-3929 dataset were similar to those in the GSE71318 dataset. The ratios of overlap among the top 50 highly expressed lncRNAs between t...
Our study paves the way for understanding the regulation of developmental events, which might be beneficial for improved reproductive outcomes....
Stable angina develops during physical activity or stress, and it is typically an aspect of Coronary Heart Disease (CHD) that can lead to arrhythmia, heart failure and even sudden death. ANRIL, an Ant...
The authors enrolled 62 patients with myocardial infarction and 59 with stable angina before primary percutaneous coronary intervention, as well as 48 healthy volunteers. Their peripheral blood was co...
The data showed that ANRIL is a better diagnostic indicator than cardiac troponin I in patients with stable angina and that the levels of ANRIL are higher in patients with stable angina than those wit...
The levels of ANRIL in peripheral plasma could be used as a good biomarker for stable angina....
Diabetic kidney disease (DKD) is a common microvascular complication of diabetes, whose complex etiology involves a genetic component....
Accumulating evidence has highlighted that lncRNA ABHD11-AS1 plays an essential role in tumorigenesis and is expected to become a new predictive biomarker and ideal target for cancer therapy, whereas ...
Eight databases were comprehensively screened for relevant articles on January 1, 2024. The significance of ABHD11-AS1 in malignancies was determined by odds ratios (ORs) or hazard ratios (HRs) with c...
Fourteen clinical studies comprising eight kinds of malignancies and 1215 malignancy cases were enrolled into this meta-analysis. The pooled results showed that increased ABHD11-AS1 expression was rem...
Current evidence supports the association of elevated ABHD11-AS1 expression with poor prognosis. Thereby, ABHD11-AS1 may be considered as a promising biomarker to screen cancer and predict malignancy ...
Regulatory T cells (Tregs) are central in controlling immune responses, and dysregulation of their function can lead to autoimmune disorders or cancer. Despite extensive studies on Tregs, the basis of...
Long noncoding RNAs (lncRNAs) are expressed in many brain circuits and types of neurons; nevertheless, their functional significance for normal brain functions remains elusive. Here, we study the func...
Clear cell renal cell carcinoma (RCC) is the most common subtype of RCC. Although targeted therapy can provide superior treatment outcomes, it is prone to drug resistance, and individual responses to ...
Small interfering RNA (siRNA) and plasmid cloning DNA (pcDNA) 3.1 were used to transfect renal cancer cell line 786-0 to silence and overexpress the lncRNA...
Compared with blank control group and negative control group, the siGPRC5D-AS1 group showed a significant decrease in the relative expression of lncRNA...
Silencing the expression of lncRNA...
A significant body of research strengthens the starring role of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in the pathogenesis of inflammatory bowel disease (IBD). Here, we investigated the...
This study included 97 participants, thirty-five ulcerative colitis patients, thirty-two Crohn's disease patients, and thirty IBD-free controls. History, staging, laboratory investigations, and colono...
The estimated serum levels for H19 and miRNA-675-5p in the UC and CD groups in comparison to the control group showed a high statistical difference (P = 0.0001 for each parameter). Based upon the seve...
H19 and miRNA-675-5p can be used as diagnostic biomarkers in IBD, with superiority in UC patients with moderate activity....